The 16a-[18F]-fluoro-17b-estradiol ([18F]FES) PET/CT has been successfully applied in breast and ovarian cancer; and [18F]FES uptake has shown a high correlation with estrogen receptor (ER) expressions in previous studies [76,77]. Here, ESR1 is linked to ovarian cancer.